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Introduction: Research involving antimitotic compounds identified 2-methoxyestradiol (2ME2), as a promising anticancer
endogenous metabolite. Owing to its low bioavailability, several in silico-designed 2ME2 analogues were synthesized.
Structure-activity relationship studies indicated that an already existing 17-β-estradiol analogue, namely
(8R,13S,14S,17S)-2-ethyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrane-3,17-diyl
bis(sulphamate) (EMBS) to exert potential in vitro anticancer activity.
Methods: This study investigated the in vitro apoptotic influence of EMBS in an estrogen receptor-positive breast
adenocarcinoma epithelial cell line (MCF-7); an estrogen receptor-negative breast epithelial cell line (MDA-MB-231) and a
non-tumorigenic breast cell line (MCF-12A). Cell cycle progression, a phosphatidylserine flip, caspase 6-, 7- and 8 enzyme
activity levels, Bcl-2 phosphorylation status at serine 70 and Bcl-2- and p53 protein levels were investigated to identify a
possible action mechanism for apoptotic induction.
Results: The xCELLigence real-time label-independent approach revealed that EMBS exerted antiproliferative activity in all
three cell lines after 24 h of exposure. A G2M block was observed and apoptosis induction was verified by means of flow
cytometry using propidium iodide and Annexin V-FITC respectively. EMBS-treated cells demonstrated a reduced
mitochondrial membrane potential. EMBS exposure resulted in a statistically significant increase in p53 protein
expression, decreased Bcl-2 protein expression and a decrease in pBcl-2(s70) phosphorylation status in all three
cell lines. Results support the notion that EMBS induces apoptosis in all three cell lines.
Conclusion: This study includes investigation into the apoptotic hallmarks exerted by EMBS after exposure of
three cell lines namely MCF-7-, MDA-MDA-231- and MCF-12A cells. Increased caspase 6-, caspase 7- and caspase
8 activities, upregulation of p53 protein expression and a decrease in phosphorylation status of Bcl-2 at serine 70
in tumorigenic and non-tumorigenic lines were demonstrated.
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For decades antimitotic agents have been studied for
their potential anticancer activity. These studies have
resulted in the discovery of 2-methoxyestradiol (2ME2),
an endogenous 17β-estradiol that exerts antiproliferative,
antiangiogenic, and anti-inflammatory activity in an
estrogen receptor-independent manner [1]. 2ME2 has
estrogen-independent activity that has stimulated sub-
stantial curiosity regarding its mechanism of action, in-
cluding its relevance as a therapeutic agent [2].* Correspondence: michelle.visagie@up.ac.za
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unless otherwise stated.Owing to its limited bioavailability, several estradiol ana-
logues have been designed in silico and subsequently syn-
thesized [3]. In structure-activity relationship studies it has
been reported that the addition of sulphamate groups
(position 3 and 17) to 2ME2 results in superior efficacy and
bioavailability [2]. This improvement is due to the sul-
phamate groups inhibiting activation of metabolism and de-
activation of conjugation and interaction with carbonic
anhydrase [4]. The sulphamate group reversibly interacts
with the catalytic site of carbonic anhydrase II, an enzyme
highly expressed in red blood cells, making it possible
for the sulphamoylated compound to bypass first pass
liver metabolism [2]. The superior bioavailability is
supported by a bis-sulphamoylated analogue (positionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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erts antiproliferative activity in several cell lines including a
lung adenocarcinoma cell line (HOP-62), a human colorec-
tal carcinoma cell line (HCT-116), human glioblastoma
cells (SF-539), a melanoma cell line (UAVC-62), a human
ovarian adenocarcinoma cell line (OVCAR-3), renal car-
cinoma cells (SN12-C), human prostate carcinoma cells
(DU-145) and a breast tumorigenic cell line (MDA-MB-
435) [5]. In addition, 2-methoxyestradiol-bis-sulphamate is
resistant to in vivo metabolisms in xenografts derived from
human melanoma (MDA-MB-435) cells. Superior activity is
demonstrated by 85% bioavailability and maintained an-
ticancer activity 28 days after treatment cessation [5].
The addition of methyl and ethyl groups to the estra-
diol results in antiproliferative and antimitotic activity
independent of the estrogen receptors. The antimitotic
ability of these compounds is due to their ability to bind
the colchicine binding-site of tubulin [6]. The latter is
supported as estradiol compounds with ethyl additions
at position 2 (2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-
tetraene and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)15-
tetraen-17-ol) exerting antimitotic activity in non-tumorigenic
MCF-12A, tumorigenic MCF-7 and metastatic MDA-
MB-231 breast cancer cells. In addition, both these de-
rivatives were found to inhibit carbonic anhydrase II
activity and mimic carbonic anhydrase IX activity in
MDA-MB-231 cells. Carbonic anhydrase II is not over-
expressed in several types of cancer contributing to the
acidic environment found in the tumours [7,8].
This study involved an estradiol compound that was
modified by the addition of an ethyl group (position 2), a
methyl group (position 3) and bis-sulphamoylation at posi-
tions 3 and 17 [4]. These chemical modifications merit in-
vestigation of possible in vitro anticancer activity exerted
by (8R,13S,14S,17S)-2-ethyl-13-methyl-7,8,9,11,12,13,14,15,
16,17-decahydro-6H-cyclopenta[a]phenanthrane-3,17-diyl
bis(sulphamate) (EMBS). The study investigated the influ-
ence of EMBS on proliferation, cell cycle progression, cas-
pase activation and subsequent apoptosis induction in an
estrogen receptor-positive breast adenocarcinoma cell line
(MCF-7), a triple negative metastatic breast cell line (MDA-




The MCF-7 cell line is an estrogen receptor-positive
tumorigenic adherent breast epithelial cell line derived
from metastatic sites in adenocarcinoma [9]. MCF-7
cells were supplied by Highveld Biological (Pty) Ltd.
(Sandringham, Gauteng, South Africa).
The MDA-MB-231 cell line is an estrogen receptor-
negative tumorigenic metastatic breast cell line and
is commercially available from Microsep (Pty) Ltd.(Johannesburg, Gauteng, South Africa) [9]. Tumorigenic
cells were grown and maintained in sterile 25 cm2 tissue
culture flasks at a humidified atmosphere at 37°C and 5%
CO2. Growth medium consisted of Dulbecco’s Minimum
Essential Medium Eagle (DMEM) supplemented with 10%
heat-inactivated fetal calf serum (56°C, 30 min), 100 U/ml
penicillin G, 100 μg/ml streptomycin and fungizone
(250 μg/l).
MCF-12A cells are non-tumorigenic transformed ad-
herent human breast epithelial cells. These cells are pro-
duced by long-term cultures and form domes in confluent
cultures [9]. The MCF-12A cells were a gift from Prof
Parker (Department of Medical Biochemistry, University of
Cape Town, Western Cape, South Africa). MCF-12A cells
were cultured in growth medium consisting of a 1:1 mix-
ture of DMEM and Ham’s-F12 medium, 20 ng/ml epider-
mal growth factor, 100 ng/ml cholera toxin, 10 μg/ml
insulin and 500 ng/ml hydrocortisone, supplemented with
10% heat-inactivated fetal calf serum (56°C, 30 min), 100
U/ml penicillin G, 100 μg/ml streptomycin and fungizone
(250 μg/l).Reagents
All required reagents of cell culture analytical grade
were purchased from Sigma (St. Louis, MI, United
States of America) unless otherwise specified. Heat-
inactivated fetal calf serum (FCS), sterile cell culture
flasks and plates were purchased from Sterilab Ser-
vices (Kempton Park, Johannesburg, Gauteng, South
Africa). Penicillin, streptomycin and fungizone were ob-
tained from Highveld Biological (Pty) Ltd. (Sandringham,
Gauteng, South Africa). The Annexin V fluorescein isothio-
cyanate (FITC) kit, Mitocapture Mitochondrial Apoptosis
Detection Kit, Caspase 6 colorimetric assay kit, the Flice/
Caspase 8 colorimetric assay, Rabbit polyclonal antibody
for anti-active caspase 7, the anti-rabbit antibody conju-
gated to Dylight™ 488, ImmunoSet p53/MDM2 Complex
Elisa development set, RIPA cell lysis buffer, TMB substrate
and Plates (ImmunoSet pack) were purchased from BIO-
COM biotech (Pty) Ltd. (Clubview, Gauteng, South Africa).
The Flow Collect Bcl-2 activation dual detection kit was
purchased from Merck Millipore (Ltd) (Billerica, MA,
United States of America).
EMBS is commercially unavailable and was synthesized
by iThemba Pharmaceuticals (Pty) Ltd. (Modderfontein,
Gauteng, South Africa) [3]. A stock solution of EMBS
dissolved in dimethyl sulphoxide (DMSO) was prepared
with a concentration of 10 mM and was stored at 4°C.
The vehicle control sample composed of DMSO and
growth medium and the DMSO content of the final
dilutions never exceeded 0.05% (v/v). In addition, cells
were exposed to actinomycin D (0.1 μg/ml; 24 h) as
positive control for apoptosis.
Figure 1 xCELLigence demonstrating effects of EMBS on
proliferation. The xCELLigence method demonstrated the in vitro
effects of EMBS on proliferation in the MCF-7 (A), MDA-MB-231 (B)
and MCF-12A cell line (C). Cell proliferation was significantly inhibited at
all concentrations in a concentration-dependent manner. However,
MCF-12A cell growth recovers after 24 h exposure of EMBS.
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Cell proliferation
The xCELLigence method is a system-based assay devel-
oped by Roche Applied Science (Penzberg, Germany) to
demonstrate cell growth, adhesion and morphology in
real-time, utilizing a label-independent manner and was
employed to demonstrate the effects of EMBS on prolifer-
ation. This system measured electrical impedance across
the micro-electrodes integrated on the bottom of tissue
culture 96-well plates allowing real-time and continuous
cellular analysis as cells attach and proliferate [10,11]. The
change in impedance was expressed as the cell index that
is an indication of cell number, cellular attachment and
morphology. By plotting cell index values over time, a pre-
cise real-time cellular analysis profile was generated. The
response of live cells to EMBS supplied proliferative and
antiproliferative information.
The RTCA SP Station was connected to the RTCA
control unit and the xCELLigence system was tested by
resistor plate verification prior to the xCELLigence sys-
tem being placed inside the incubator at a humidified
atmosphere at 37°C and 5% CO2. Background quantifica-
tion was done by adding 100 μl of the appropriate
growth medium to the wells. Subsequently the plate was
calibrated using RTCA software package 1.2. Cells were
seeded at 5000 cells per well, placed on a rotator for
30 min at room temperature and cells were subsequently
placed in the xCELLigence system linked to the incuba-
tor in a humidified atmosphere at 37°C and 5% CO2
[10,11]. The xCELLigence system monitored cell adhe-
sion and proliferation for 24 h to allow for attachment.
Subsequently, cells were exposed to 0.2-1 μM EMBS
concentration series since previous studies demonstrated
optimal antiproliferative activity after 0.4 μM EMBS ex-
posure for 24 h [12]. As the cells multiplied, the elec-
trical impedance created by the cells was converted to
cell index values corresponding to each well. These cell
index values are then directionally proportionate to cell
number, size and attachment. Cell adhesion and prolifer-
ation were measured for the next 72 h.
Cell cycle progression
Flow cytometry and propidium iodide was utilized to in-
vestigate the DNA content to determine cell cycle distribu-
tion, G2/M block and the presence of a sub-G1 apoptotic
peak [13]. After 24 h of exposure to 0.4 μM EMBS, cells
were trypsinized and resuspended in 1 ml growth medium.
Cells (1 × 106) were centrifuged for 5 min at 300x g. The
pellet was resuspended twice in ice-cold phosphate buffer
solution (PBS). The supernatant was discarded and cells
were resuspended in 200 μl of ice-cold PBS containing
0.1% FCS. Ice-cold 70% ethanol (4 ml) was added in a
drop-wise manner and cells were stored at 4°C for 24 h.
After 24 h, cells were pelleted by centrifugation for5 min. The supernatant was removed and cells were
resuspended in 1 ml of PBS containing propidium iodide
(40 μg/ml) and incubated at 37°C, 5% CO2 for 45 min.
Cells were then analyzed by means of FACS FC500 System
flow cytometer (Beckman Coulter South Africa (Pty) Ltd)
equipped with an air-cooled argon laser excited at
488 nm. Data from at least 10 000 cells were captured with
CXP software (Beckman Coulter South Africa (Pty) Ltd,
Johannesburg, Gauteng, South Africa] and analyzed with
Cyflogic (CyFlo Ltd., Turku, Finland).
Apoptosis induction
The presence of apoptosis was evaluated and quantified
using flow cytometry in combination with Annexin
V-fluorescein isothiocyanate (FITC). In apoptosis, the
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is activated which results in the externalization of the
phosphatidylserine layer of the cell membrane [14].
Externalization of the phosphatidylserine layer during
apoptosis provides binding sites for Annexin V. Annexin
V (a Ca2+-dependent, phospholipid binding protein) isFigure 2 Effects of EMBS on cell cycle progression. Flow cytometrical inves
cell cycle progression. Cell cycle progression of vehicle-treated MCF-7 (A), M
occupied the G1 phase and S phase, less than 2% of cells in the sub-G1 fra
exposed to 0.4 μM for 24 h. EMBS-treated MCF-7 (D), MDA-MB-231 (E) and
peak and a statistically significant increased number of cells occupied the G
experiments each performed in triplicate with a paired student’s t-test. MC
actinomycin D used as a positive control for apoptosis induction resulted i
G2M phase.conjugated to a fluorochrome; this allows for identification
of early- and late apoptosis and necrosis [14]. After 24 h of
exposure to 0.4 μM EMBS, cells were trypsinized and 106
cells were resuspended in 1 ml of 1x Binding Buffer and
centrifuged at 300x g for 10 min. Supernatant was removed
and cells were resupended in 100 μl of 1x Binding Buffer.tigation using propidium iodide and ethanol fixation demonstrated
DA-MB-231 (B) and MCF-12A cells (C) revealed the majority of cells
ction, and 13-19% of cells occupying the G2M phase. Treated cells were
MCF-12A cells (F) revealed a statistically significant increased sub-G1
2M phase. Statistical significance was indicated on 3 independent
F-7 (G), MDA-MB-231 (H) and MCF-12A cells (I) exposed to 0.1 μg/ml
n apoptosis induction and an increase of cells occupying the
Figure 3 (See legend on next page.)
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Figure 3 Change in percentage sub-population when compared to cells propagated in growth medium. Percentage change after exposure to
EMBS- and actinomycin D in the sub-G1 peak (A), G1 phase (B), S phase (C) and G2M phase (D). The percentage change in sub-G1 peak was
significant after exposure to both EMBS and actinomycin D in all three cell lines. In addition, actinomycin D (positive control) resulted in a
large percentage change in all three cell lines. The decrease in cells occupying the G1 phase after treatment to EMBS and actinomycin D
resulted in a percentage change. The G2M phase experienced a large percentage change after exposure to EMBS in all three cell lines most
prominently observed in the MDA-MB-231 cell line indicating that EMBS results in mitotic arrest.
Table 1 Flow cytometry employing propidium iodide and
ethanol fixation demonstrating cell cycle progression
Sub G1 G1 S G2M
MCF-7 cells
Vehicle-treated cells 1.16% 73.53% 11.43% 13.86%
EMBS-treated cells 36%* 3.14% 10.92% 50%*
Actinomycin D-treated cells 62.7%* 4.46% 8.72% 24.13%
MDA-MB-231
Vehicle-treated cells 0.64% 68.95% 15.16% 15.23%
EMBS-treated cells 27.9%* 2.66% 6.45% 63%*
Actinomycin D-treated cells 71%* 4.97% 5.38% 18.69%
MCF-12A cells
Vehicle-treated cells 0.78% 68.33% 12.42% 18.45%
EMBS-treated cells 32.5%* 4.14% 11.69% 51.7%*
Actinomycin D-treated cells 45.4%* 4.06% 9.85% 40.7%*
A * demonstrates a statistically significant P value of <0.05 when compared to
vehicle-treated cells.
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15 min in the dark at room temperature. After 15 min, cells
were washed by adding 1 ml of 1x Binding Buffer and cen-
trifuged at 300x g for 10 min. Supernatant was carefully re-
moved and cells were resuspended in 500 μl of 1x Binding
Buffer solution. Immediately prior to analysis, 12.5 μl of
propidium iodide (40 μg/ml) was added and samples were
mixed gently. Propidium iodide fluorescence (oncotic cells)
and annexin V fluorescence (apoptotic cells) were measured
with FC500 System flow cytometer (Beckman Coulter
South Africa (Pty)Ltd.) equipped with an air-cooled argon
laser excited at 488 nm. Data from at least 30 000 cells were
analyzed with CXP software (Beckman Coulter South
Africa (Pty) Ltd). Propidium iodide emits light at 617 nm
and FITC emits light at 530 nm. Data were obtained from
the log forward scatter detector nr 1 (FL1 Lin, 515–545 nm
emissions) and the log forward scatter detector nr 3 (FL3
Lin, 600 nm emissions) were represented as a single dot-
plot. Distributions of cells within the quadrants were calcu-
lated with Cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland).
Mitochondrial membrane potential
Further studies were conducted that employed flow cy-
tometry and Mitocapture Mitochondrial Apoptosis Detec-
tion Kit to demonstrate the apoptosis pathway utilized by
EMBS. Mitochondrial integrity was investigated by means
of a unique cationic dye – 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide [8]. Reduc-
tion of the mitochondrial membrane potential is an
early feature of apoptosis, which is due to the loss of
the electrochemical gradient across the mitochondrial
membrane [15]. Cells (500 000) were seeded with an
overnight attachment policy. After 24 h of exposure to
0.4 μM EMBS, cells were detached using trypsin and
centrifuged at 13,000x g. Cells (500 000) were resus-
pended in 1 ml of diluted Mitocapture solution (1 μl
mitocapture: 1 ml pre-warmed incubation buffer) incu-
bated in a humidified atmosphere (37°C, 5% CO2).
After 20 min, cells were centrifuged at 500x g, the
supernatant discarded and cells resuspended in 1 ml of
prewarmed incubation buffer (37°C). Cells were ana-
lyzed with a FC500 System flow cytometer (Beckman
Coulter South Africa (Pty) Ltd.). Apoptotic cells were
detected in the FITC channel (usually FL1) and showed
diffused green fluorescence. Data from at least 10 000cells were analyzed by means of Cyflogic version 1.2.1
software (Pertu Therho, Turko, Finland).
Caspase activation
Possible activation of caspase 6 and −8 were investigated
by means of caspase 6 and FLICE/caspase 8 colorimetric
kits, respectively. Caspase 7 activation was demonstrated
using flow cytometry and rabbit anti-active caspase 7.
This allowed for verification of apoptosis induction as
caspase 7 and −8 are executioner caspases and caspase
8 is an initiator caspase involved in the death receptor
pathway [16].
Caspase 6 and caspase 8
Cells (500 000) were seeded with an overnight attachment
policy. Subsequently, cells were exposed to 0.4 μM EMBS for
24 h. Cells were trypsinized and centrifuged at 12 000 rpm.
Subsequently 500 000 cells were resuspended in 50 μl of
chilled cell lysis buffer and incubated on ice for 10 min. Cells
were centrifuged at 10 000x g for 1 min and the supernatant
incubated on ice. After the protein concentration had been
determined with the use of the BCA protein assay (Thermo
Fisher Scientific, Johannesburg, Gauteng, South Africa),
100 μg protein/50 μl cell lysis buffer was mixed with
50 μl 2x reaction buffer (containing 10 mM DTT). After-
wards, 5 μl 4 mM Ac-Leu-Glu-His-Asp-p-nitroanilide
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Glu-Thr-Asp-p-nitroanilide (Ac-IETD-pNA) (caspase-8-
specific substrate) (200 μM final concentration) were
added and incubated at 37°C for 120 min. Absorbances
were determined at 405 nm on the ELx800 Universal
Microplate Reader available from Bio-Tek Instruments
Inc. (Winooski, VT, United States of America).Figure 4 Apoptosis induction by EMBS exposure. Apoptosis induction w
V-FITC. Vehicle-treated MCF-7 (A), MDA-MB-231 (B) MCF-12A cells (C), EM
actinomycin D-treated MCF-7 (G), MDA-MB-231 (H) and MCF-12A (I). Tre
increase in cells undergoing late apoptosis and necrosis when compared
positive control for apoptosis induction resulted in decreased cell viabilit
represented on the x-axis and FL1 log (FITC) was represented on the y-axCaspase 7
Cells were seeded at 500 000 cells per flask and after
24 h of attachment, cells were exposed to 0.4 μM EMBS
for 24 h. Subsequently, cells were trypsinized and 500
000 cells were centrifuged and the medium was dis-
carded. Cells were then resuspended in wash buffer and
centrifuged. The supernatant was removed and cells wereas also verified using flow cytometry, propidium iodide and annexin
BS-treated MCF-7 (D), MDA-MB-231 (E), MCF-12 A cells (F) and
ated cells demonstrated decreased cell viability accompanied by an
to vehicle treated cells. Actinomycin D-treated cells used as a
y and apoptosis induction. FL3 log (propidium iodide) was
is.
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incubated for 20 min at room temperature. Afterwards,
the supernatant was removed; cells were resuspended in
assay buffer (1% bovine serum albumin) and centrifuged.
Cells were resupended in 500 μl ice-cold permeabilization
buffer (100% methanol) and put on ice for 10 min and
subsequently washed twice in assay buffer. Cells were
incubated with 15 μg/ml primary antibody (rabbit anti-
active caspase 7) (100 μl) on ice for 90 min after which
900 μl assay buffer was added. After centrifugation
samples were washed twice with 500 μl assay buffer, cen-
trifuged and resuspended in 100 μl assay buffer with
0.2 μg/ml anti-rabbit antibody conjugated to Dylight™ 488
fluorochrome. Samples were incubated on ice for 60 min
in the dark, 900 μl assay buffer added and washed as
before. Fluorescence was then measured using the FL1
channel with a FC500 System flow cytometer equipped
with an air-cooled argon laser excited at 488 nm (Beckman
Coulter South Africa (Pty)Ltd). Data from at least 10 000
cells were analyzed with CXP software (Beckman Coulter
South Africa (Pty) Ltd).
Expression of p53
The tumor suppressor p53 protein is essential for gen-
etic integrity and is mutated in over half of all human
cancers [17]. The influence of EMBS on p53 protein ex-
pression was demonstrated with the use of spectropho-
tometry. Cells were seeded at a density of 5 000 cells per
96 wells and left for 24 h to allow for attachment. Cells
were exposed to 0.4 μM EMBS for 24 h. After the expos-
ure period, 100 μl assay buffer (mixed according to sup-
pliers’ instructions) was added to the control wells.
Standards (100 μl) and samples prepared in assay buffer
were added to the wells. The plate was sealed and incu-
bated for 1 h at room temperature. Wells were emptiedTable 2 Flow cytometry using annexin V-FITC demonstrating
and necrotic cells
Viable cells Cells occupying early
MCF-7 cells
Vehicle-treated cells 99.3% 0.3%
EMBS-treated cells 65.5%* 0.0%
Actinomycin D-treated cells 49.3%* 0.0%
MDA-MB-231
Vehicle-treated cells 98.6% 0.0%
EMBS-treated cells 65.4%* 0.7%
Actinomycin D-treated cells 48.4%* 9.3%
MCF-12A cells
Vehicle-treated cells 98.6% 1.1%
EMBS-treated cells 66.13%* 17.4%
Actinomycin D-treated cells 46.57%* 32.71%*
A * demonstrates a statistically significant P value of <0.05 when compared to vehiand washed with 400 μl wash buffer thrice. The detection
antibody (100 μl) (mixed according to suppliers instruc-
tions) was added to each sample, except to the blank, and
the plate was sealed for 1 h. Wells were emptied and
washed thrice with 400 μl wash buffer. TMB solution
(100 μl) was pipetted into each well and the plate was
sealed at room temperature. After 30 min, 1 N hydrochloric
acid was added and absorbance was read at 450 nm using
ELx800 Universal Microplate Reader (Bio-Tek Instruments
Inc., Vermont, United States of America).
Bcl-2 expression
Bcl-2 is an anti-apoptotic protein belonging to the B-cell
lymphoma-2 (BCL-2) family. Bcl-2 opposes apoptosis by
binding to the proapoptotic members and neutralizing
their activity [18]. Flow cytometry demonstrated the
in vitro effects of EMBS on Bcl-2 protein expression and
Bcl-2 phosphorylation at position 70. Exponentially grow-
ing MCF-7, MDA-MB-231 and MCF-12A cells were
seeded at 500 000 cells per 25 cm2 flask. After 24 h
of attachment, the medium was discarded and cells
were exposed to 0.4 μM EMBS for 24 h. Cells were
trypsinized and washed with 1x wash buffer. Samples
were centrifuged and fixation buffer (0.5 ml) was
added to the samples and incubated at room temperature
for 20 min. Samples were centrifuged for 3 min and resus-
pended in 0.5 ml 1 X assay buffer. After centrifugation
(2500 rpm) samples were resuspended in ice-cold 1 X
permeabilization buffer, left on ice for 10 min and centri-
fuged at 2500 rpm and resuspended in 0.5 ml assay buffer
and centrifuged again. Samples were stained using 5 μl
20 X antibody (as described by suppliers) and incubated in
the dark. After 60 min, 900 μl 1 X assay buffer was added
to the samples and cells were centrifuged for 3 min
(2500 rpm). Samples were resuspended in 1 ml 1 X assayviable cells, cells in early apoptosis, cells in late apoptosis
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ometer (Beckman Coulter South Africa (Pty) Ltd). Data
from at least 10 000–30 000 cells were analyzed by
means of Cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland).
Statistics
Data were obtained from 3 independent experiments. All
methods conducted in 96-well plates were carried out in
triplicate for each independent experiment. Fluorescent
measurement was expressed as a ratio of the value mea-
sured for the EMBS-treated cells compared to vehicle-
treated exposed cells (mean relative fluorescence). FlowFigure 5 Effects of EMBS on the mitochondrial membrane potential. Mitot
cells (C), EMBS-treated MCF-7 (D), MDA-MB-231 (E), MCF-12 A cells (F) and
An increase was observed in the number of cells with reduced mitochond
vehicle-treated control.cytometry analysis involved data from at least 10 000
events that were repeated thrice, after which a representa-
tive figure was chosen for each experiment. Flow cytome-
try data were analyzed by means of Cyflogic version 1.2.1
software (Pertu Therho, Turko, Finland).
Results
Cell proliferation
A real-time label-independent method was used to
measure cell adhesion and cell proliferation after a 24 h
exposure of MCF-7, MDA-MB-231 and MCF-12A cells
to EMBS (Figure 1). Cell proliferation was inhibited in
all 3 cell lines (0.2-1 μM) with decreased cell indexracker-stained vehicle-treated MCF-7 (A), MDA-MB-231 (B) MCF-12A
actinomycin D-treated MCF-7 (G), MDA-MB-231 (H) and MCF-12A (I).
rial potential after treatment with EMBS when compared to the
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line recovered within 24 h after exposure at the lower
doses (0.2-0.6 μM). MDA-MB-231 cell line recovered only
after 48 h exposure with less cell proliferation when
compared to the vehicle-treated cells. MCF-12A also dem-
onstrated salvaged proliferation after 24 h exposure indi-
cating that the cell line recovered at the lower doses.
Cell cycle progression
Flow cytometry, propidium iodide staining and ethanol
fixation was used for the quantification of cell cycle pro-
gression, G2M block and the presence of apoptosis. Apop-
tosis was indicated by the existence of a sub-G1 phase
after exposure to 0.4 μM EMBS for 24 h in MCF-7,
MDA-MB-231 and MCF-12A cells (Figures 2, 3 and
Table 1). Cell cycle progression after exposure to EMBS
resulted in a statistically significant increased sub-G1 peak
in MCF-7 (36%), MDA-MB-231 (28%) and MCF-12A cells
(33%). Furthermore, EMBS exposure also produced a sta-
tistically significant increase of MCF-7 (50%), MDA-MB-
231(63%) and MCF-12A cells (52%) occupying the G2M
phase. By contrast, actinomycin D treatment resulted in a
general, non cell type specific sub-G1 population, with en-
richment in the G2M phase, to a lesser extent than for
EMBS treatment.
Apoptosis induction
The presence of apoptosis was investigated by means of
flow cytometry and Annexin V-FITC (Figure 4 and
Table 2). After exposure to EMBS, (0.4 μM, 24 h)
MCF-7 cell viability decreased to 66% with 0.1% of
cells found present in early apoptosis, 22.21% in late
apoptosis and 12.25% in necrosis when compared to
vehicle-treated cells. After exposure to EMBS, MDA-
MB-231 cell viability decreased to 65% with 0.68% of
cells found present in early apoptosis, 21.61% in lateFigure 6 Caspase 6 activation by EMBS. Caspase 6 activity ratios of EMBS-
EMBS-treated MDA-MB-231 cells possessed the highest caspase 6 activity, f
used as a positive control for apoptosis and caspase activation and display
vehicle-treated cells.apoptosis and 12.31% in necrosis when compared to
vehicle-treated cells. After exposure to EMBS, MCF-
12A cell viability decreased to 66% with 17% of cells
found present in early apoptosis, 11.44% in late apop-
tosis and 5.11% in necrosis when compared to vehicle-
treated cells.
Mitochondrial membrane potential
Further investigation of the intrinsic pathway was per-
formed by demonstrating the effects of EMBS (0.4 μM,
24 h) on the mitochondrial membrane potential (Figure 5).
After EMBS exposure 22%, 26% and 21% of MCF-7,
MDA-MB-231 and MCF-12A cells possessed mitochon-
drial depolarization.
Caspase activation
Apoptosis induction was also investigated by demonstrat-
ing the effect of EMBS (0.4 μM, 24 h) on caspase 6, −7
and −8 activity in MCF-7, MDA-MB-231 and MCF-12A
cells lines. Results indicated that EMBS exposure resulted
in increased caspase 6-, caspase 7- and caspase 8 activity
when compared to vehicle-treated cells. Caspase 6 colori-
metric assay revealed that MDA-MB-231 cells were more
pronouncedly affected followed by MCF-7 cells when
compared to vehicle-treated cells (Figure 6). EMBS-
treated cells showed increased caspase 7 activity (23-28%)
when compared to vehicle-treated cells (Figure 7). Cas-
pase 8 colorimetric assay also suggested that MDA-MB-
231 cells were pronouncedly affected followed by MCF-7
when compared to vehicle-treated cells regarding caspase
8 activity (Figure 8).
Expression of p53
This study also demonstrated p53 involvement in apoptosis
induction by EMBS (0.4 μM, 24 h). Spectrophotometrical
data indicated that EMBS exposure resulted in a statisticallyand actinomycin D-treated cells compared to vehicle-treated cells.
ollowed by MCF-7 and MCF-12A. Actinomycin D-treated cells were
ed significant elevated caspase 6 activity when compared to
Figure 7 Caspase 7 activation by EMBS. Caspase 7 activity of vehicle-treated MCF-7 (A), MDA-MB-231 (B) MCF-12A cells (C), EMBS-treated MCF-7 (D),
MDA-MB-231 (E), MCF-12 A cells (F) and actinomycin D-treated MCF-7 (G), MDA-MB-231 (H) and MCF-12A (I). Data showed an increase in the number
of cells with increased caspase 7 activity after exposure to EMBS when compared to cells vehicle-treated cells. Actinomycin D-treated cells were used
as a positive control for apoptosis and caspase activation and displayed significant elevated caspase 7 activity when compared to vehicle-treated cells.
Visagie et al. Cell & Bioscience  (2015) 5:19 Page 11 of 15significant increase of p53 protein expression (Figure 9).
The p53 protein expression of MCF-7 cells was the most
pronouncedly affected, followed by MDA-MB-231 cells and
MCF-12A cells.
Bcl-2 expression
Bcl-2 protein expression and phosphorylation status at
Serine 70 of Bcl-2 was investigated using a specialized
Flow Collect Bcl-2 activation dual detection kit and flow
cytometry. Cells treated with EMBS possessed downreg-
ulated Bcl-2 protein expression and a decrease in pBcl-2
(s70) phosphorylation status when compared to cells
propagated in growth medium and vehicle-treated cells
(Figure 10 and Table 3).Discussion
Microtubule agents have been studied for decades as ef-
fective anticancer agents resulting in the in silico-design
of several estradiol analogues and subsequent synthesis
[3]. This in vitro study investigated the influence of a
17-beta estradiol analogue, EMBS, on proliferation, cell
cycle progression and apoptosis induction in an adeno-
carcinoma receptor positive cell line (MCF-7), estrogen
receptor-negative metastatic cell line (MDA-MB-231) and
a non-tumorigenic epithelial breast cell line (MCF-12A).
The xCELLigence system demonstrated successful anti-
proliferative activity in an estrogen-independent manner.
This was supported by another recent study conducted in
our laboratory that reported successful antiproliferation
Figure 8 Caspase 8 activation by EMBS. Caspase 8 activity ratios of EMBS- and actinomycin D-treated cells compared to vehicle-treated cells.
EMBS-treated MDA-MB-231 cells possessed the highest caspase 8 activity, followed by MCF-7 and MCF-12A. Actinomycin D-treated cells were
used as a positive control for apoptosis and caspase activation and displayed significant elevated caspase 8 activity above 2.5 fold when
compared to vehicle-treated cells.
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MB-231 and MCF-12A cell lines [12]. EMBS was previ-
ously found to exert antiproliferative activity in cell lines
including lung adenocarcinoma cell line (HOP-62), human
colorectal carcinoma cell line (HCT-116), human glioblast-
oma cell line (SF-539), melanoma cell line (UAVC-62), hu-
man ovarian adenocarcinoma cell line (OVCAR-3), renal
carcinoma cell line (SN12-C), human prostate carcinoma
cell line (DU-145) and a breast tumorigenic cell line
(MDA-MB-435) [19]. Previous studies have also re-




17one reduced cell growth in a similar concentration
range that was observed in this study [9,20,21].
Cell cycle progression studies have revealed that
EMBS exposure (0.4 μM; 24 h) results in a statisticallyFigure 9 Effects of EMBS on p53 expression. The protein expression of p53
protein expression of EMBS-treated MCF-7 cells were the most profoundly
cells propagated in growth medium and vehicle-treated cells.significantly increased number of cells occupying the
G2M phase and subsequent apoptosis induction verified
by means of flow cytometry employing annexin V-
FITC. Antimitotic activity exerted by EMBS is sup-
ported by findings of a previous study that revealed an
increase in cells trapped in metaphase resulting in
apoptosis [12]. In addition, this study also suggests that
EMBS exposure results in apoptosis induction by means
of depolarisation of the mitochondrial membrane and cas-
pase 6, −7 and −8 activation in all three cell lines. Previous
studies have reported that exposure to 2-ethyl-3-O-sul-
phamoyl-estra-1, 3, 5 (10) 16-tetraene and 2-ethyl-3-
O-sulphamoyl-estra-1, 3, 5 (10) 15-tetraene-3-ol-17one
resulted in increased caspase 6 and caspase 8 activity [21].
In addition, 2-ethyl-3-O-sulphamoyl-estra-1, 3, 5 (10) 16-
tetraene, 2-ethyl-3-O-sulphamoyl-estra-1, 3, 5 (10) 15-
tetraene-3-ol-17one reduced the mitochondrial membrane
potential in the human cervical adenocarcinoma cell linewas significantly increased when exposed to 0.4 μM for 24 h. The p53
affected, followed by MCF-12A and MDA-MB-231 when compared to
Figure 10 Effects of EMBS on Bcl-2 expression and pBcl-2(s70) phosphorylation. Flow cytometry investigation of Bcl-2 expression (FL1 Log) and
pBcl-2(s70) phosphorylation (FL3 Log) of vehicle-treated MCF-7 (A), MDA-MB-231 (B) and MCF-12A cells (C). Treated cells were exposed to 0.4 μM
for 24 h and demonstrated a downregulated protein expression of Bcl-2 and pBcle-2(s70) phosphorylation status in MCF-7 (D), MDA-MB-231 (E)
and MCF-12A cells (F). Actinomycin D-treated cells were used as a positive control for apoptosis and showed a decrease in Bcl-2 protein expression
and Bcl-2(s70) phosphorylation status in MCF-7 (G), MDA-MB-231 (H) and MCF-12A cells (I).
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brane potential suggests apoptosis induction via the intrin-
sic pathway. EMBS exposure produced depolarization of
the mitochondrial membrane potential and cytochrome c
release in MDA-MB-231 cell line and human umbilical
vein endothelial cell line (HUVEC) [22]. The increased
quantity of cells possessing reduced mitochondrial mem-
brane potential and increased caspase 8 activity indicates
that EMBS induces apoptosis by means of both the intrin-
sic and extrinsic pathways.
Spectrophotometry results revealed that EMBS-treated
cells exhibited increased p53 protein expression. Thefinding is supported by reports that another sulpha-
moylated analogue, 2-ethylestrone-3-sulfamate upregu-
lated p53 expression in CAL-51 cell lines, HUVEC cell
lines and MCF-7 cells line [23,24]. The p53 tumor sup-
pressor is the primary mediator of proliferation arrest,
senescence, and apoptosis induction. In unstressed cells
murine double minute 2 (MDM2), the main antagonist
of p53, continuously monoubiquitinates p53 and therefore
this is the essential step in regulating its degradation by
nuclear and cytoplasmic proteosomes [25]. Increased
p53 protein expression after exposure to EMBS sug-
gests the presence of decreased MDM2 and Akt














Vehicle-treated cells 99.2% 0.6% 0.1% 0.0%
EMBS-treated cells 63.06%* 0.0% 14.2% 22.69%*
Actinomycin D-treated cells 36.53%* 54.38%* 9.0% 0.0%
MDA-MB-231 cells
Vehicle-treated cells 99.3% 0.0% 0.3% 0.3%
EMBS-treated cells 61.75%* 9.5% 17.4% 11.4%
Actinomycin D-treated cells 27.78%* 65.13%* 7.1% 0.0%
MCF-12A cells
Vehicle-treated cells 99.1% 0.1% 0.7% 0.0%
EMBS-treated cells 70.14%* 0.6% 10.9% 18.3%
Actinomycin D-treated cells 35.07%* 50.18%* 35.07%* 0.4%
*Statistical significance at P <0.05 compared to vehicle-treated cells in a paired student T-test.
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cluding Bcl-2-Associated X Protein (BAX), Fas/Apo1,
Killer/death receptor 5 (DR5), PUMA, Noxa, AFAF1 and
Bcl-2 [26]. Gene array studies conducted in our laboratory
revealed that BAX expression was increased in the
MDA-MB-231 cell line after exposure to EMBS [27].
Transcriptional upregulation by p53 of BAX results in
a conformational change and triggers the intrinsic
apoptotic pathway [28].
Unregulated p53 expression is supported by the de-
creased Bcl-2 protein expression and a decrease in pBcl-
2(s70) phosphorylation status after exposure to EMBS
when compared to vehicle-treated cells. Bcl-2 is an anti-
apoptotic protein that occurs on the cytoplasmic face of
the mitochondrial outer membrane and endoplasmic
reticulum. Bcl-2 alters the cellular organelle’s behaviour
by modifying the flux of small molecules or proteins
[29]. Bcl-2 protects against apoptosis by stabilization the
mitochondrial membrane potential. This stabilization
prevents the release of cytochrome c and activation of
caspase 2 and caspase 9 [30]. Thus this study suggests
that apoptosis induction is also mediated by decreased
p53- and Bcl-2 protein expression accompanied by de-
creased pBcl-2(s70) phosphorylation status.
Conclusion
In conclusion, the aims of this study namely, to investigate
the effects of EMBS in breast adenocarcinoma cell lines
(MCF-7 and MDA-MB-231) and the non-tumorigenic epi-
thelial breast cell line (MCF-12A) respectively by analyzing
its influence on cell growth, cell cycle progression and
apoptosis induction were achieved. EMBS exposure re-
sulted in antiproliferative-and antimitotic activity and
induced apoptosis in an estrogen receptor-independentmanner. The induction of both the intrinsic- and ex-
trinsic apoptotic pathway by EMBS exposure is impli-
cated. Data collected in this study indicate that EMBS
induces intrinsic apoptosis by means of a reduction in
the mitochondrial membrane potential that results in
the activation of caspases 6- and −7 accompanied with
a decrease in Bcl-2 protein expression and pBcl-2(s70)
phosphosphorylation status. The involvement of the
extrinsic apoptotic pathway is also indicated by the
activation of caspase 8. EMBS exposure resulted in in-
creased caspase 6-, caspase 7- and caspase 8 activity,
upregulated p53 protein expression and a decrease in
phosphorylation status of Bcl-2 at serine 70 in tumorigenic
and non-tumorigenic lines. Data contribute to the unravel-
ling of the signalling mechanism utilized by EMBS in breast
tumorigenic and non-tumorigenic cell lines and to the de-
velopment and/or improvement of novel chemotherapeutic
agents paving the way for efficient in vivo studies.Competing interests
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